2023
Case report: Coronary atherosclerosis in a patient with long-standing very low LDL-C without lipid-lowering therapy
Mottola G, Welty F, Mojibian H, Faridi K. Case report: Coronary atherosclerosis in a patient with long-standing very low LDL-C without lipid-lowering therapy. Frontiers In Cardiovascular Medicine 2023, 10: 1272944. PMID: 37795488, PMCID: PMC10546007, DOI: 10.3389/fcvm.2023.1272944.Peer-Reviewed Case Reports and Technical NotesLipid-lowering therapyLDL-C levelsCoronary atherosclerosisLow LDL-C levelsLow-density lipoprotein cholesterolCardiovascular risk factorsLeft coronary systemRight coronary arteryLow serum levelsDevelopment of atherosclerosisNonobstructive coronary atherosclerosisRoutine laboratory dataTomography angiography scansApoB-containing lipoproteinsHeterozygous familial hypobetalipoproteinemiaAnomalous originMyxoma resectionAcute strokeAtrial myxomaCardiovascular riskLipoprotein cholesterolPlaque regressionDiabetes mellitusPrimordial preventionSerum levelsMoving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease
Faridi K, Desai N. Moving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease. American Journal Of Preventive Cardiology 2023, 14: 100491. PMID: 36969953, PMCID: PMC10036885, DOI: 10.1016/j.ajpc.2023.100491.Commentaries, Editorials and Letters
2022
Rationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID)
Shah NN, Ghazi L, Yamamoto Y, Martin M, Simonov M, Riello RJ, Faridi KF, Ahmad T, Wilson FP, Desai NR. Rationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID). American Heart Journal 2022, 253: 76-85. PMID: 35841944, PMCID: PMC9936562, DOI: 10.1016/j.ahj.2022.07.002.Peer-Reviewed Original ResearchConceptsLipid-lowering therapyAtherosclerotic cardiovascular diseaseTreatment of hyperlipidemiaProportion of patientsElectronic health recordsPragmatic trialHigh riskCardiovascular diseaseProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsHigh-risk atherosclerotic cardiovascular diseaseSubtilisin/kexin type 9 inhibitorsLow-density lipoprotein cholesterol reductionImportant public health implicationsEnrollment of patientsPublic health implicationsUsual careSecondary outcomesPrimary outcomeGuideline recommendationsCholesterol reductionPatientsLDLHyperlipidemiaScalable interventionsOutpatients
2017
Serum vitamin D and change in lipid levels over 5 y: The Atherosclerosis Risk in Communities study
Faridi KF, Zhao D, Martin SS, Lupton JR, Jones SR, Guallar E, Ballantyne CM, Lutsey PL, Michos ED. Serum vitamin D and change in lipid levels over 5 y: The Atherosclerosis Risk in Communities study. Nutrition 2017, 38: 85-93. PMID: 28526388, PMCID: PMC5443111, DOI: 10.1016/j.nut.2017.01.008.Peer-Reviewed Original ResearchConceptsIncident dyslipidemiaLipid changesLongitudinal community-based studyAdjusted average differencesDemographic-adjusted modelsLipid-lowering therapySerum vitamin DCommunity-based studyBaseline dyslipidemiaLipid trendsIncident useCardiovascular riskClinical characteristicsSD ageVitamin DARIC studyAtherosclerosis RiskCardiovascular diseaseLipid levelsDyslipidemiaCommunity studyRatio of TCHDLMixed effects modelsBaseline